SCHEMBL22627130

SCHEMBL22627130

O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)Nc1ccc(Oc2ccnc(C(=O)NO)c2)cc1F

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 9/20 0.85
BRAF P15056 6/20 0.85
KDR P35968 5/20 0.85
PDGFRB P09619 4/20 0.85
RET P07949 3/20 0.85
RIPK2 O43353 2/20 0.85
ABCB11 O95342 2/20 0.85
ABL1 P00519 2/20 0.85
HTR1A P08908 2/20 0.85
ADORA3 P0DMS8 2/20 0.85
KIT P10721 2/20 0.85
FGFR1 P11362 2/20 0.85
PDGFRA P16234 2/20 0.85
FLT1 P17948 2/20 0.85
MAOA P21397 2/20 0.85
EPHA1 P21709 2/20 0.85
TBXA2R P21731 2/20 0.85
EPHA2 P29317 2/20 0.85
TTK P33981 2/20 0.85
EPHX2 P34913 2/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Regorafenib SCHEMBL29351376 0.92 RAF1 (1.00) RAF1BRAFKDRPDGFRBRET
Regorafenib SCHEMBL432230 0.92 RAF1 (1.00) RAF1BRAFKDRPDGFRBRET
Regorafenib SCHEMBL29349808 0.92 RAF1 (1.00) RAF1BRAFKDRPDGFRBRET
Regorafenib SCHEMBL2554008 0.91 RAF1 (0.98) RAF1BRAFKDRPDGFRBRET
Regorafenib SCHEMBL2555101 0.91 RAF1 (0.98) RAF1BRAFKDRPDGFRBRET
Regorafenib SCHEMBL29555444 0.91 RAF1 (0.98) RAF1BRAFKDRPDGFRBRET
Regorafenib SCHEMBL29496390 0.91 RAF1 (0.98) RAF1BRAFKDRPDGFRBRET
SCHEMBL4609009 0.91 BRAF (0.82) RAF1BRAFKDRPDGFRBRET
SCHEMBL4737847 0.91 KDR (1.00) RAF1BRAFKDRPDGFRBRET
SCHEMBL15114774 0.91 RAF1 (0.81) RAF1BRAFKDRPDGFRBRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200345637-A1 SUSPENSION COMPOSITIONS OF MULTI-TARGET INHIBITORS AIVIVA BIOPHARMA, INC. 2020-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200345637-A1 SUSPENSION COMPOSITIONS OF MULTI-TARGET INHIBITORS ACP3, KLK3, BPHL RAF1 1436/4885BRAF 972/4885KDR 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.